Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2008-03-27 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Annual Report 2007
Annual Report FY 2007
2008-03-27 English
Report of Periodic or Interim Report
Annual Report Classification · 95% confidence The document is a detailed announcement of financial results for the year ended December 31, 2007, including comprehensive financial data such as revenues, expenses, operating loss, and balance sheet information. It contains actual financial statements and analysis, not just a summary or announcement of a report. The presence of full financial data and discussion of business operations and outlook indicates this is a full annual financial report. The document is not a brief earnings release or a regulatory filing announcing the report's availability, but a substantive financial disclosure. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2007
2008-03-20 Hebrew (modern)
Report of Periodic or Interim Report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli regulations. Crucially, it mentions 'Attached hereto is a report on *Financial Results for the Year Ended December 31, 2007*' and lists a PDF file named '2007XTLEarningsReleaseFinal_isa.pdf'. Since the document itself is short and serves to announce the availability of the detailed financial results (the 'meal'), it fits the definition of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) or a detailed Earnings Release (ER). The content is an announcement about the publication of the results.
2008-03-20 English
Immediate Report
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing deal between XTL Biopharmaceuticals and Presidio Pharmaceuticals for a pre-clinical program in Hepatitis C. It details the terms of the licensing agreement, upfront payments, milestone payments, and royalties. The document does not contain financial statements, regulatory certifications, or detailed financial performance data. It is not an earnings release or a financial report but rather a corporate announcement about a capital-related transaction (licensing deal) that impacts the company's financial position and future revenue streams. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6436 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or regulatory filing. No mention of voting results, board changes, or legal proceedings is present. Hence, the classification is CAP with high confidence.
2008-03-20 Hebrew (modern)
Immediate Report
Report Publication Announcement Classification · 98% confidence The document is very short (1725 characters) and explicitly states it is an 'Immediate Report' under Israeli regulations. Crucially, it announces that a report/press release is attached: 'Attached hereto is a report on *XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre-Clinical Program in Hepatitis C to Presidio Pharmaceuticals*' and lists the attached file name. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or is attached should be classified as a Report Publication Announcement (RPA). It is not the full financial report (10-K, IR) or a specific transaction report (like DIRS or DIV), but rather the announcement of a corporate event/press release.
2008-03-20 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., reporting financial results for the year ended December 31, 2007. It includes detailed financial data such as statements of operations and balance sheet information, as well as management commentary on the financial results and business developments. The document is not a full annual report (like a 20-F), but rather a periodic report providing comprehensive financial results and analysis for a fiscal year. The presence of detailed financial statements and analysis indicates it is a financial report rather than a simple announcement or certification. Form 6-K is typically used by foreign private issuers to report material information, including financial results, to the SEC. Given the detailed financial results and discussion, this document fits best as an Interim / Quarterly Report (IR) type, since it is a periodic financial report shorter than a full annual report and contains substantive financial data and analysis. Confidence is high due to the detailed financial content and the nature of the filing.
2008-03-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.